# Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

> **NCT04991025** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer
- Lung Cancer Stage II
- Lung Cancer Stage III

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Certolizumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04991025
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-19
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991025, "Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04991025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*